Mesoblast Limited
MEOBF
$1.37
-$0.25-15.43%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 0.00% | 25.54% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.00% | 25.54% | |||
| Cost of Revenue | 0.00% | -130.26% | |||
| Gross Profit | 0.00% | 150.70% | |||
| SG&A Expenses | 0.00% | 41.53% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 0.00% | -46.91% | |||
| Total Operating Expenses | 0.00% | -31.74% | |||
| Operating Income | 0.00% | 36.33% | |||
| Income Before Tax | 0.00% | 14.02% | |||
| Income Tax Expenses | 0.00% | 338.20% | |||
| Earnings from Continuing Operations | 0.00% | 13.50% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 0.00% | 13.50% | |||
| EBIT | 0.00% | 36.33% | |||
| EBITDA | 0.00% | 38.04% | |||
| EPS Basic | 0.00% | 14.98% | |||
| Normalized Basic EPS | 0.00% | 7.75% | |||
| EPS Diluted | 0.00% | 14.98% | |||
| Normalized Diluted EPS | 0.00% | 7.75% | |||
| Average Basic Shares Outstanding | 0.00% | 1.81% | |||
| Average Diluted Shares Outstanding | 0.00% | 1.81% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
